Tumor cell reactivity mediated by IgM antibodses in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies

Cancer Immunology Immunotherapy

Volumn 43, Issue 6, 1997, Pages 324-330

  Livingston, Philip ^a   Zhang, Shengle ^a   Adluri, Sucharita ^a   Yao, Tzy Jynn ^a   Graeber, Linda ^a   Ragupathi, Govindaswami ^a   Helling, Friedhelm ^a,b   Fleisher, Martin ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CHIRON VACCINES   (Italy)

Author keywords

Complement; Conjugate vaccine; Fractionation; GM2 ganglioside; Melanoma; Vaccine

Indexed keywords

BCG VACCINE; GANGLIOSIDE GM2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KEYHOLE LIMPET HEMOCYANIN; MELANOMA VACCINE; QS 21;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNIZATION; MELANOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL;

ANTIBODIES, NEOPLASM; CANCER VACCINES; G(M2) GANGLIOSIDE; HAPTENS; HEMOCYANIN; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MELANOMA;

EID: 0031054219     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050340     Document Type: Article

References (26)

1. Hamilton WB, Helling F, Lloyd KO, Livingston PO (1993) Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer 53: 566-573
2. Hamilton WB, Helling F, Livingston PO (1993) Ganglioside expression on sarcoma and small-cell lung carcinoma compared to tumors of neuroectodermal origin (abstract). Proc Am Assoc Cancer Res 34: 491
3. Tsuchida T, Saxton RE, Morton DL, Irie RF (1989) Gangliosides of human melanoma. Cancer 63: 1166-1174
4. Cheung N-KV, Lazarus H, Miraldi FD, Abramowsaky CR, Kallic S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA (1987) Ganglioside GD2 specific monoclonal antibody 3F8: a phase-I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 5: 1430-1440
5. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ (1985) Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase-I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82: 1242-1246
6. Irie RF, Morton DL (1986) Regression of cutaneous metastatic melanoma by introlesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 83: 8694-8698
7. Irie RF, Matsuki T, Morton DL (1989) Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet I: 786-787
8. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russel CH, LoBuglio AF (1992) Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 52: 4342-1347
9. Livingston PO, Ritter F, Srivastava P, Padavan M, Calves MJ, Oettgen HF, Old LJ (1984) Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49: 7045-7050
10. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G, Oettgen HF, Old LJ (1994) Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12: 1036-1044
11. Livingston PO, Natoli EJ Jr, Calves MJ, Stockert H, Oettgen HF, Old LJ (1987) Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84: 2911-2915
12. Helling F, Shang A, Calves M, Zhang S, Ren S, Yu RK, Oettgen HF, Livingston PO (1994) Increased immunogenicity of GD3 conjugate vaccines: comparison of various carrier proteins and selection of GD3-KLH for further testing. Cancer Res 54: 197-203
13. Helling F, Zhang A, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Oettgen HF, Livinston PO (1995) GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55: 2783-2788
14. Livingston PO, Adluri S, Helling F, Yao T-J, Kensil CR, Newman MJ, Marciani D (1994) Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma. Vaccine 12: 1275-1280
15. Kitamura K, Livingston PO, Fortunato SR, Stockert E, Helling F, Ritter G, Oettgen HF, Old LJ (1995) Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci USA 92: 2503-2507
16. Zhang S, Helling F, Lloyd KO, Livingston PO (1995) Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. Cancer Immunol Immunother 40: 88-94
17. Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ (1976) Cell surface antigens of human malignant melanoma: I. Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cell's. Proc Natl Acad Sci USA 73: 3278-3282
18. Shiku H, Takahashi T, Oettgen HF, Old LJ (1976) Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two surface antigens. J Exp Med 144: 873-881
19. Gosling JP (1990) A decade of development in immunoassay methodology. Clin Chem 36: 1408-1427
20. Bjornson AB, Michael JG (1970) Biological activities of rabbit immunoglobulin M and immunoglobulin G antibodies to Pseudomonas aeruginosa. Infect Immun 2: 453-461
21. Pier GB, Thomas D, Small G, Siadak A, Zweerink H (1989) In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide. Infect Immun 57: 174-179
22. Raff HV, Bradley C, Brady W, Donaldson K, Lipsich L, Maloney G, Shuford W, Walls M, Ward P, Wolff E, Harris LJ (1991) Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B Streptococci or Escherichia coli K1. J Infect Dis 163: 346-352
23. Wolff EA, Esselstyn J, Maloney G, Raff HV (1992) Human monoclonal antibody homodimers. Effect of valency on in vitro and in vivo antibacterial activity. J Immunol 148: 2469-2474
24. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF (1981) Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 33: 249-254
25. Shitara K, Fujiwara K, Igarashi S, Ohta, S, Furuya A, Nakamura K, Koike M, Hanai N (1994) Immunoglobulin class switch of antiganglioside monoclonal antibody from IgM to IgG. J Immunol Methods 169: 83-92
26. Nakamura K, Koike M, Shitara K, Kuwana Y, Kiuragi K, Igarashi S, Hasegawa M, Hanai N (1994) Chimeric anti-GM2 antibody with antitumor activity. Cancer Res 54: 1511-1516